Back to Search
Start Over
Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST‐Segment Elevation Myocardial Infarction?
- Source :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Publication Year :
- 2015
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2015.
-
Abstract
- Background A pharmacoinvasive ( PI ) strategy for early presenting ST ‐segment elevation myocardial infarction nominally reduced 30‐day cardiogenic shock and congestive heart failure compared with primary percutaneous coronary intervention ( PPCI ). We evaluated whether infarct size ( IS ) was related to this finding. Methods and Results Using the peak cardiac biomarker in patients randomized to PI versus PPCI within the Strategic Reperfusion Early After Myocardial Infarction ( STREAM ) trial, IS was divided into 3 groups: small (≤2 times the upper limit normal [ ULN ]), medium (>2 to ≤5 times the upper limit normal) and large (>5 times the upper limit normal). The association between IS and 30‐day shock and congestive heart failure was subsequently examined. Data on 1701 of 1892 (89.9%) patients randomized to PI (n=853, 50.1%) versus PPCI (n=848, 49.9%) within STREAM were evaluated. A higher proportion of PPCI patients had a large IS ( PI versus PPCI : small, 49.8% versus 50.2%; medium, 56.9% versus 43.1%; large, 48.4% versus 51.6%; P =0.035), despite comparable intergroup ischemic times for each reperfusion strategy. As IS increased, a parallel increment in shock and congestive heart failure occurred in both treatment arms, except for the small IS group. The difference in shock and congestive heart failure in the small IS group (4.4% versus 11.6%, P =0.026) in favor of PI likely relates to higher rates of aborted myocardial infarction with the PI strategy (72.7% versus 54.3%, P =0.005). After adjustment, a trend favoring PI persisted in this subgroup (relative risk 0.40, 95% CI 0.15 to 1.06, P =0.064); no difference in treatment‐related outcomes was evident in the other 2 groups. Conclusion A PI strategy appears to alter the pattern of IS after ST ‐segment elevation myocardial infarction, resulting in more medium and fewer large infarcts compared with PPCI . Despite a comparable number of small infarcts, PI patients in this group had more aborted myocardial infarctions and less 30‐day shock and congestive heart failure. Clinical Trial Registration URL : http://ClinicalTrials.gov . Unique identifier: NCT 00623623.
- Subjects :
- Male
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Myocardial Infarction
Shock, Cardiogenic
Myocardial Reperfusion
Coronary Angiography
Risk Assessment
Electrocardiography
Percutaneous Coronary Intervention
Risk Factors
Internal medicine
Pexelizumab
medicine
infarct size
Creatine Kinase, MB Form
Humans
Thrombolytic Therapy
Prospective Studies
Myocardial infarction
Original Research
Aged
Heart Failure
medicine.diagnostic_test
business.industry
Myocardium
Cardiogenic shock
Percutaneous coronary intervention
Middle Aged
primary percutaneous coronary intervention
medicine.disease
ST-segment elevation myocardial infarction
Treatment Outcome
Shock (circulatory)
Heart failure
Cardiology
Platelet aggregation inhibitor
Female
pharmacoinvasive
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Biomarkers
Platelet Aggregation Inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 20479980
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- Journal of the American Heart Association
- Accession number :
- edsair.doi.dedup.....4c4e4d64a213af77ed4479757eb2a9bf